IP Library Granted Patent US 12,194,102
Granted Patent B2
US 12,194,102 · App. 18/175,020 · Granted Jan 14, 2025

Compositions for enhancing bioavailability of pharmaceuticals, supplements and ingested substances

Inventors: Andrew R. Lefkowitz (Solon, OH); Sean Farmer (Ft. Lauderdale, FL); Ken Alibek (Solon, OH)
Assignee: LOCUS SOLUTIONS IPCO, LLC
A61K47/26A61K9/5123A61K47/42
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,194,102
App. No.
18/175,020
Filed
Feb 27, 2023
Granted
Jan 14, 2025
Kind
B2
Art Unit
1615
USPC
424/451
Abstract

The present invention relates to compositions and methods for enhancing bioavailability of health-promoting substances, such as pharmaceuticals and nutritional supplements. The subject invention utilizes an adjuvant composition comprising one or more microbial-produced biosurfactants and/or isoforms thereof, to enhance bioavailability of health-promoting substances and to reduce the effective dosage that is required.

Claims (6)

1. A method for administering a health-promoting substance to a tissue in a subject, the method comprising administering, to the subject, an effective amount of a composition comprising a purified sophorolipid, a purified mannosylerythritol lipid (MEL), and said health-promoting substance; wherein said health-promoting substance is an antibiotic or an anti-inflammatory substance; and

wherein said composition is administered to the subject via transdermal or cutaneous administration; and

wherein the health-promoting substance is encapsulated in a nanocapsule formed by the sophorolipid and the MEL.

2. The method of claim 1 , wherein the composition further comprises a pharmaceutically-acceptable carrier.

3. The method of claim 1 , wherein the sophorolipid, the MEL, or both the sophorolipid and the MEL, are present in the composition in critical micelle concentration (CMC).

4. The method of claim 1 , wherein at least 60% by weight of said purified sophorolipid is in an acidic form.